Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients.
BACKGROUND
Hepatitis C virus (HCV) infection acquired during dialysis treatment generally shows a relatively benign course after renal transplantation (RTx). However, less is known about the course of HCV infection acquired during or after RTx.


METHODS
Clinical and histopathological assessment of 15 renal transplant recipients who acquired HCV infection during or after RTx.


RESULTS
Alanine aminotransferase levels rose for the first time 1-19 weeks after RTx. HCV RNA was found positive in all patients, but anti-HCV became positive in only nine of them. During a mean follow-up of 21 +/- 12 months, jaundice appeared in 12 patients while ascites and/or hepatic encephalopathy occurred in six. Azathioprine was stopped in all patients. Cyclosporin was also stopped in four patients and in two of them prednisolone was also interrupted for a period of 3-7 weeks. Following this, ascites, hepatic encephalopathy and biochemical disturbances improved, while no deterioration was seen in graft function. Nine of the 15 patients had undergone two consecutive liver biopsies (LB). The first LB revealed cirrhosis in three and chronic hepatitis in six patients; the second LB showed cirrhosis in seven patients. The histological activity index (Knodell's score) progressed from 11.8 +/- 3.5 to 13.8 +/- 3.8.


CONCLUSIONS
The results suggest that HCV infection acquired during or after RTx may run an unusual and rapidly progressive clinical and histopathological course at least in some of these patients. Decrease or withdrawal of immunosuppressive drugs may improve early hepatic failure without detrimental effect on graft function during that period.
Ok
E
E
Department of Nephrology, Ege University Medical School, Bornova, Izmir, Turkey.
Unsal
A
A
Celik
A
A
Zeytinoğlu
A
A
Ersöz
G
G
Tokat
Y
Y
Erensoy
S
S
Akarca
U S
US
Basçi
A
A
Yüce
G
G
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D018450:Disease Progression; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology*; D018937:Hepatitis C Antibodies / Q000032:analysis*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007431:Intraoperative Complications; D016030:Kidney Transplantation / Q000276:immunology; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012333:RNA, Messenger / Q000378:metabolism; D013997:Time Factors
D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D000410:Alanine Transaminase